# RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

> **NCT01490086** · PHASE2 · COMPLETED · sponsor: **Reviva Pharmaceuticals** · enrollment: 234 (actual)

## Conditions studied

- Acute Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** RP5063
- **DRUG:** placebo
- **DRUG:** aripiprazole

## Key facts

- **NCT ID:** NCT01490086
- **Lead sponsor:** Reviva Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01490086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01490086, "RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01490086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*